July 2008

Pennsylvania Consortium: Clinical Database

Conditions:   Amyotrophic Lateral Sclerosis;   Neurodegenerative Disease;   Motor Neuron Disease
Intervention:  
Sponsors:   Drexel University College of Medicine;   MDA/ALS Center of Hope
Terminated - verified June 2016

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

Condition:   Autoimmune Disease
Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified February 2017

Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program

Conditions:   Amyotrophic Lateral Sclerosis;   Neurodegenerative Disease;   Motor Neuron Disease
Intervention:  
Sponsors:   Drexel University College of Medicine;   MDA/ALS Center of Hope
Completed - verified January 2017

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Conditions:   Non-Hodgkin's Lymphoma;   Leukemia;   Multiple Myeloma;   Acute Myeloid Leukemia;   Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions:   Biological: Thymoglobulin;   Radiation: Total-Body Irradiation;   Procedure: Allogeneic PBSCT or BMT;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
Sponsors:   Virginia Commonwealth University;   Genzyme, a Sanofi Company
Active, not recruiting - verified October 2016